Bipolar Disorder News

A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.

Published results showed no statistically significant associations between mental health conditions, such as depression, anxiety, bipolar disorder, trauma and schizophrenia, and outcomes after total joint arthroplasty.

Factors previously associated with short-term risk for new-onset bipolar disorder also were associated with significantly higher risk after more than 10 years of follow-up, according to a study published in JAMA Network Open.

A clinical-stage biopharmaceutical company has announced the submission of an investigational new drug application to the FDA based upon results of a phase 2a clinical study of a novel lithium delivery system, AL001, for bipolar disorder.

Continuing adjunctive antidepressant therapy for 52 weeks after depressive episode remission in patients with bipolar 1 disorder did not significantly delay further mood episodes vs. stopping treatment after 8 weeks, according to a study.

BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.

Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.

SAN FRANCISCO — Diagnosis and treatment of mood and anxiety disorders experienced late in life require detailed medical and psychological history, according to a presenter at the American Psychiatric Association annual meeting. .

SAN FRANCISCO — Collaboration and communication between mental and physical health services is crucial to overcome logistics of providing proper care for homeless individuals in a large city, Carine Nzodom, MD, says in a Healio video.

MIAMI BEACH, Fla. — Telepsychiatry may be a safe and effective tool to treat bipolar disorder in adolescents and adults, but deeper research is needed, according to a poster at the American Society of Psychopharmacology annual meeting.